Physician
NPI deactivated
New York City Health and Hospitals Corporation
New York City Health and Hospitals Corporation was paid $160.32M by Medicaid between Jan 2018 and Dec 2024, across 709 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoNEW YORK CITY HEALTH AND HOSPITALS CORPORATION
BRONX, NY 10451
BRONX, NY 10451
33aNPI1427063270assigned 07/30/2006
33bProvider typeInternal Medicine Physician
28Total paid$160.32M
24GClaims3,954,456
24DCodes billed709
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in New York
Rank by total paid#4 of 6,049
Median peer was paid$11K
This provider vs. median14,172×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KARLIN, MARJI controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 92,064 | $605K | |
| 2019 | 258,431 | $8.68M | |
| 2020 | 641,967 | $26.15M | |
| 2021 | 941,825 | $36.42M | |
| 2022 | 876,900 | $37.46M | |
| 2023 | 585,418 | $25.53M | |
| 2024incomplete | 557,851 | $25.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 152,478 | 140,097 | $27.43M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.8% | 77,845 | 70,646 | $14.13M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.4% | 173,208 | 153,260 | $13.41M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 5.4% | 91,611 | 82,044 | $8.64M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.9% | 32,018 | 30,297 | $6.21M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.9% | 82,662 | 71,600 | $4.67M |
| 36415 | Collection of venous blood by venipuncture | 2.6% | 303,637 | 155,850 | $4.14M |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.8% | 27,141 | 26,555 | $2.88M |
| S9083 | Global fee urgent care centers | 1.7% | 26,470 | 24,329 | $2.78M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.6% | 41,924 | 38,293 | $2.61M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.5% | 15,068 | 14,760 | $2.36M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 11,601 | 11,239 | $2.19M |
697 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 21,942 | $1.89M |
| 99285 | Emergency room visit (most serious) | 1.1% | 9,954 | $1.72M |
| 90834 | Psychotherapy session, about 45 minutes | 1.1% | 9,845 | $1.70M |
| G0378 | Hospital observation service, per hour | <1% | 1,272 | $1.50M |
| 81408 | <1% | 1,065 | $1.33M | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 9,097 | $1.32M |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 70,922 | $1.25M |
| 99442 | <1% | 19,496 | $1.14M | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 1,502 | $1.01M |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 8,328 | $995K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 14,152 | $966K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 22,981 | $894K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,720 | $852K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,455 | $851K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 51,066 | $835K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,842 | $813K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,748 | $806K |
| D9999 | Unspecified adjunctive procedure, by report | <1% | 5,800 | $770K |
| D0999 | Unspecified diagnostic procedure, by report | <1% | 4,808 | $767K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 90,081 | $751K |
| 99205 | Prolong outpt/office vis | <1% | 3,865 | $750K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 27,817 | $725K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,907 | $683K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 11,793 | $675K |
| 76818 | <1% | 5,788 | $666K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 5,843 | $662K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 8,574 | $644K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 21,043 | $627K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 14,803 | $614K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 7,235 | $597K |
| 86480 | <1% | 11,614 | $589K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 11,304 | $582K |
| 76641 | <1% | 4,941 | $569K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 29,405 | $564K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 23,877 | $524K |
| 99441 | <1% | 12,335 | $516K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 44,491 | $510K |
| 52000 | <1% | 684 | $507K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 11,932 | $494K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,853 | $481K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 45,701 | $467K |
| 99443 | <1% | 6,310 | $465K | |
| 0002A | <1% | 14,572 | $454K | |
| 87536 | <1% | 4,702 | $438K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 3,005 | $437K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 22,826 | $434K |
| 76770 | <1% | 2,953 | $429K | |
| 99051 | <1% | 12,890 | $426K | |
| 0001A | <1% | 15,090 | $426K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,669 | $423K |
| 80053 | Comprehensive metabolic panel | <1% | 41,064 | $415K |
| 77066 | Tomosynthesis, mammo | <1% | 2,774 | $406K |
| H0049 | Alcohol and/or drug screening | <1% | 7,574 | $389K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 47,883 | $386K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 7,179 | $379K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 26,237 | $378K |
| 80061 | Lipid panel | <1% | 38,577 | $375K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,825 | $369K |
| 86703 | <1% | 29,620 | $362K | |
| 90677 | <1% | 2,838 | $354K | |
| 85027 | <1% | 131,350 | $352K | |
| 70486 | <1% | 2,637 | $346K | |
| 12001 | <1% | 1,592 | $346K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 15,262 | $335K |
| 12011 | <1% | 1,615 | $333K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,476 | $331K |
| 90651 | <1% | 3,432 | $327K | |
| H0050 | Alcohol and/or drug services, brief intervention, per 15 minutes | <1% | 6,463 | $326K |
| H2011 | Crisis intervention service, per 15 minutes | <1% | 1,587 | $325K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 46,938 | $321K |
| J2357 | Injection, omalizumab, 5 mg | <1% | 386 | $313K |
| 80076 | <1% | 54,047 | $303K | |
| 86360 | <1% | 6,282 | $300K | |
| 90461 | <1% | 17,389 | $298K | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 1,135 | $294K |
| 71250 | <1% | 1,651 | $292K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,572 | $287K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 10,191 | $284K |
| 59025 | Fetal non-stress test | <1% | 2,795 | $281K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 12,612 | $279K |
| 99201 | <1% | 4,247 | $278K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,364 | $276K |
| 86850 | <1% | 15,932 | $264K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 9,608 | $257K |
| 90715 | <1% | 11,318 | $247K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,446 | $244K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,461 | $240K |
| 90750 | <1% | 3,159 | $238K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,182 | $234K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 3,172 | $233K |
| 86359 | <1% | 6,275 | $231K | |
| 12002 | <1% | 1,077 | $229K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 22,926 | $227K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,107 | $223K |
| 82948 | <1% | 50,889 | $220K | |
| 81161 | <1% | 1,101 | $209K | |
| 81329 | <1% | 1,690 | $202K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,800 | $189K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,436 | $188K |
| 99381 | <1% | 6,632 | $186K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,670 | $184K |
| 90686 | <1% | 21,421 | $183K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,719 | $178K |
| 10060 | <1% | 1,184 | $175K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,751 | $174K |
| 76830 | Ultrasound, transvaginal | <1% | 3,706 | $171K |
| 86901 | <1% | 15,930 | $171K | |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 2,528 | $161K |
| 97802 | <1% | 7,072 | $158K | |
| 0004A | <1% | 4,330 | $158K | |
| 86780 | <1% | 18,381 | $156K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 7,888 | $156K |
| 81025 | <1% | 34,978 | $154K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,750 | $153K |
| 93970 | <1% | 702 | $151K | |
| J0517 | Injection, benralizumab, 1 mg | <1% | 270 | $150K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,476 | $142K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 866 | $140K |
| 59841 | <1% | 249 | $140K | |
| 97010 | <1% | 20,094 | $137K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 3,363 | $137K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 362 | $136K |
| 29580 | <1% | 1,554 | $130K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,635 | $130K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 771 | $129K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,706 | $128K |
| D7210 | Extraction, erupted tooth requiring removal of bone and/or sectioning of tooth | <1% | 3,205 | $128K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,826 | $127K |
| 97161 | <1% | 1,362 | $124K | |
| T1013 | Sign language or oral interpretive services, per 15 minutes | <1% | 11,025 | $123K |
| 86900 | <1% | 15,891 | $121K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 119 | $116K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 166 | $111K |
| 76642 | <1% | 1,329 | $110K | |
| D0330 | Panoramic radiographic image | <1% | 5,929 | $110K |
| D0140 | Limited oral evaluation - problem focused | <1% | 9,348 | $110K |
| 73610 | <1% | 5,683 | $109K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 3,253 | $108K |
| 86803 | <1% | 11,562 | $108K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 3,898 | $106K |
| 57452 | <1% | 539 | $106K | |
| 73630 | <1% | 5,850 | $106K | |
| 87800 | <1% | 3,595 | $106K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,331 | $104K |
| 83655 | <1% | 9,674 | $104K | |
| 71045 | Radiologic examination, chest; single view | <1% | 14,411 | $100K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,409 | $97K |
| 96127 | <1% | 29,894 | $97K | |
| 11900 | <1% | 1,004 | $97K | |
| 88142 | <1% | 4,249 | $96K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 2,737 | $96K |
| 76536 | <1% | 972 | $93K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 504 | $92K |
| 77062 | <1% | 591 | $92K | |
| 97803 | <1% | 2,055 | $90K | |
| 73564 | <1% | 3,935 | $90K | |
| 90746 | <1% | 1,721 | $90K | |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 3,732 | $90K |
| 81422 | <1% | 165 | $88K | |
| 72100 | <1% | 3,862 | $86K | |
| 86769 | <1% | 3,545 | $85K | |
| 76820 | <1% | 1,811 | $84K | |
| 76801 | <1% | 1,098 | $84K | |
| 97124 | <1% | 3,115 | $83K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,221 | $82K |
| 83880 | <1% | 5,668 | $80K | |
| 90732 | <1% | 878 | $79K | |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 150 | $78K |
| 73030 | <1% | 4,634 | $78K | |
| 74019 | <1% | 3,193 | $77K | |
| 81001 | <1% | 49,693 | $75K | |
| 73130 | <1% | 4,869 | $75K | |
| 93975 | <1% | 456 | $74K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 11,368 | $74K |
| 81243 | <1% | 1,630 | $73K | |
| 73110 | <1% | 4,003 | $73K | |
| 87340 | <1% | 10,193 | $72K | |
| 77336 | <1% | 324 | $72K | |
| 76825 | <1% | 277 | $71K | |
| 92250 | <1% | 1,821 | $70K | |
| 83970 | <1% | 2,599 | $70K | |
| 29125 | <1% | 636 | $69K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,418 | $69K |
| 99401 | <1% | 3,458 | $68K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,731 | $67K |
| D1110 | Prophylaxis - adult | <1% | 3,554 | $67K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 3,392 | $67K |
| 90697 | <1% | 3,116 | $66K | |
| H0001 | Alcohol and/or drug assessment | <1% | 395 | $66K |
| 92567 | <1% | 2,678 | $66K | |
| 93971 | <1% | 1,407 | $65K | |
| 92579 | <1% | 1,192 | $65K | |
| 86003 | <1% | 2,270 | $64K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,797 | $64K |
| 17110 | <1% | 392 | $63K | |
| 0072A | <1% | 1,499 | $63K | |
| 97167 | <1% | 577 | $62K | |
| 84153 | <1% | 4,409 | $61K | |
| 0071A | <1% | 1,589 | $61K | |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 72 | $59K |
| 20610 | <1% | 702 | $59K | |
| S9088 | Services provided in an urgent care center (list in addition to code for service) | <1% | 1,086 | $58K |
| 86762 | <1% | 4,829 | $58K | |
| 92557 | <1% | 1,782 | $58K | |
| 77049 | <1% | 153 | $56K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 268 | $56K |
| 86706 | <1% | 7,189 | $55K | |
| 83020 | <1% | 4,363 | $53K | |
| 73562 | <1% | 2,455 | $53K | |
| J0882 | Injection, darbepoetin alfa, 1 microgram (for esrd on dialysis) | <1% | 275 | $52K |
| 84702 | <1% | 14,044 | $52K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 140 | $52K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,850 | $51K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 768 | $51K |
| 87535 | <1% | 1,490 | $51K | |
| 90670 | <1% | 4,913 | $50K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 263 | $50K |
| 92133 | <1% | 1,381 | $48K | |
| 90734 | <1% | 1,534 | $48K | |
| 84439 | <1% | 6,221 | $44K | |
| D9430 | <1% | 2,844 | $44K | |
| 76870 | <1% | 714 | $42K | |
| 77412 | <1% | 193 | $41K | |
| 73590 | <1% | 3,094 | $41K | |
| 97162 | <1% | 419 | $41K | |
| 19083 | <1% | 62 | $41K | |
| 94375 | <1% | 891 | $40K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 81 | $40K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,535 | $39K |
| 90620 | <1% | 1,459 | $39K | |
| 76000 | <1% | 459 | $39K | |
| 82951 | <1% | 3,786 | $39K | |
| 96367 | <1% | 2,145 | $38K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 495 | $38K |
| 94729 | <1% | 787 | $38K | |
| 0124A | <1% | 938 | $38K | |
| 74178 | <1% | 126 | $37K | |
| 99383 | <1% | 684 | $37K | |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 3,170 | $36K |
| 99382 | <1% | 608 | $36K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,284 | $36K |
| 83735 | <1% | 33,365 | $35K | |
| 92083 | <1% | 647 | $35K | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 5,863 | $35K |
| 92015 | Determination of refractive state | <1% | 1,558 | $34K |
| 82728 | <1% | 4,010 | $34K | |
| 99384 | <1% | 801 | $33K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 487 | $32K |
| 73502 | <1% | 1,655 | $31K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 141 | $31K |
| 84484 | <1% | 24,837 | $30K | |
| 92582 | <1% | 332 | $30K | |
| 91320 | <1% | 680 | $30K | |
| 82105 | <1% | 2,451 | $30K | |
| 82043 | <1% | 7,114 | $29K | |
| 93325 | <1% | 1,217 | $29K | |
| 82607 | <1% | 3,388 | $29K | |
| 73090 | <1% | 2,292 | $29K | |
| 85610 | <1% | 13,467 | $29K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 476 | $28K |
| 82803 | <1% | 3,821 | $28K | |
| 77080 | <1% | 1,092 | $27K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 61 | $27K |
| 82785 | <1% | 1,933 | $27K | |
| 81002 | <1% | 8,362 | $27K | |
| 94726 | <1% | 469 | $27K | |
| 73565 | <1% | 779 | $26K | |
| 93923 | <1% | 252 | $26K | |
| 86765 | <1% | 2,523 | $26K | |
| 87486 | <1% | 1,789 | $26K | |
| 81405 | <1% | 149 | $25K | |
| 77061 | <1% | 189 | $25K | |
| 90739 | <1% | 264 | $24K | |
| 80320 | <1% | 9,637 | $24K | |
| 73700 | <1% | 124 | $24K | |
| 87081 | <1% | 5,845 | $24K | |
| 90656 | <1% | 2,117 | $24K | |
| 70491 | <1% | 118 | $23K | |
| 86787 | <1% | 2,526 | $23K | |
| D0120 | Dental checkup, returning patient | <1% | 2,637 | $23K |
| 84402 | <1% | 970 | $23K | |
| 85730 | <1% | 11,212 | $23K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 717 | $23K |
| 86735 | <1% | 2,412 | $22K | |
| 73080 | <1% | 1,562 | $22K | |
| 96161 | <1% | 4,587 | $22K | |
| 90480 | <1% | 761 | $22K | |
| 76821 | <1% | 253 | $22K | |
| D0274 | Bitewings - four radiographic images | <1% | 2,399 | $21K |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 1,601 | $21K |
| 84100 | <1% | 24,740 | $21K | |
| 70498 | <1% | 115 | $21K | |
| 82677 | <1% | 1,073 | $21K | |
| 87517 | <1% | 498 | $21K | |
| 88104 | <1% | 430 | $21K | |
| 87631 | <1% | 642 | $21K | |
| 87581 | <1% | 1,790 | $21K | |
| 90698 | <1% | 4,140 | $21K | |
| 90707 | <1% | 1,556 | $20K | |
| 88108 | <1% | 446 | $20K | |
| 51798 | <1% | 130 | $20K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 26,812 | $19K |
| 90674 | <1% | 972 | $19K | |
| 81361 | <1% | 190 | $19K | |
| 95819 | <1% | 44 | $19K | |
| 90633 | <1% | 3,038 | $19K | |
| 73120 | <1% | 864 | $19K | |
| 83001 | <1% | 1,048 | $19K | |
| 82274 | <1% | 1,941 | $19K | |
| 76827 | <1% | 277 | $19K | |
| 73600 | <1% | 1,022 | $18K | |
| 83550 | <1% | 3,629 | $18K | |
| 58300 | <1% | 165 | $18K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,711 | $18K |
| S0190 | Mifepristone, oral, 200 mg | <1% | 286 | $18K |
| 84146 | <1% | 984 | $18K | |
| 0003A | <1% | 451 | $18K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,384 | $18K |
| 90846 | Family psychotherapy without the patient present, 50 minutes | <1% | 128 | $18K |
| D1120 | Dental cleaning, child | <1% | 2,169 | $17K |
| 86704 | <1% | 1,930 | $17K | |
| 95117 | <1% | 1,397 | $17K | |
| 83690 | <1% | 21,439 | $16K | |
| 83525 | <1% | 1,444 | $16K | |
| 73140 | <1% | 1,112 | $16K | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,292 | $15K |
| 90716 | <1% | 1,519 | $15K | |
| 11982 | <1% | 53 | $15K | |
| 97164 | <1% | 238 | $15K | |
| 94060 | <1% | 424 | $15K | |
| 83540 | <1% | 3,809 | $15K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 40 | $15K |
| 87186 | <1% | 3,522 | $15K | |
| 74018 | <1% | 836 | $15K | |
| 90681 | <1% | 2,866 | $15K | |
| 84403 | <1% | 598 | $15K | |
| 73552 | <1% | 1,114 | $15K | |
| 88304 | <1% | 542 | $14K | |
| 81401 | <1% | 182 | $14K | |
| 96910 | <1% | 111 | $14K | |
| 83002 | <1% | 781 | $14K | |
| 73560 | <1% | 539 | $14K | |
| 73070 | <1% | 1,024 | $13K | |
| 96417 | <1% | 212 | $13K | |
| 73620 | <1% | 745 | $13K | |
| 84704 | <1% | 1,072 | $13K | |
| 82550 | <1% | 12,727 | $13K | |
| 90744 | <1% | 2,424 | $13K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 24,930 | $13K |
| 72040 | <1% | 563 | $12K | |
| 73060 | <1% | 1,039 | $12K | |
| 81257 | <1% | 205 | $12K | |
| 73100 | <1% | 546 | $12K | |
| 82570 | <1% | 4,734 | $12K | |
| 51741 | <1% | 65 | $12K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 2,698 | $12K |
| 90733 | <1% | 103 | $12K | |
| 97014 | <1% | 841 | $12K | |
| 92550 | <1% | 373 | $11K | |
| 86336 | <1% | 1,072 | $11K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 8,385 | $11K |
| 83605 | <1% | 10,378 | $11K | |
| 84154 | <1% | 711 | $11K | |
| 76857 | <1% | 297 | $11K | |
| 58301 | <1% | 64 | $11K | |
| 72070 | <1% | 447 | $11K | |
| 92650 | <1% | 341 | $11K | |
| 82805 | <1% | 1,641 | $11K | |
| 0081A | <1% | 246 | $11K | |
| 12013 | <1% | 36 | $10K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,610 | $10K |
| 82746 | <1% | 1,106 | $10K | |
| 88300 | <1% | 761 | $10K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 2,755 | $10K |
| 82533 | <1% | 564 | $10K | |
| D9310 | <1% | 328 | $9K | |
| 93226 | <1% | 182 | $9K | |
| 71271 | <1% | 51 | $9K | |
| 11104 | <1% | 59 | $9K | |
| 70496 | <1% | 84 | $9K | |
| 99385 | <1% | 145 | $9K | |
| J2356 | Injection, tezepelumab-ekko, 1 mg | <1% | 13 | $9K |
| 51702 | <1% | 100 | $9K | |
| 81381 | <1% | 69 | $9K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,701 | $9K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 85 | $9K |
| D1206 | Topical application of fluoride varnish | <1% | 2,152 | $9K |
| 96523 | <1% | 237 | $9K | |
| 86038 | <1% | 1,101 | $8K | |
| 82248 | <1% | 2,452 | $8K | |
| 84550 | <1% | 3,160 | $8K | |
| 86592 | <1% | 2,574 | $8K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,503 | $8K |
| 99493 | <1% | 144 | $8K | |
| 72050 | <1% | 286 | $8K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,566 | $8K |
| 84156 | <1% | 3,018 | $8K | |
| 71101 | <1% | 563 | $8K | |
| 0082A | <1% | 174 | $8K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 37 | $8K |
| 83516 | <1% | 732 | $8K | |
| 87338 | <1% | 799 | $8K | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 736 | $8K |
| 83615 | <1% | 2,370 | $7K | |
| 97139 | <1% | 453 | $7K | |
| 95930 | <1% | 3,147 | $7K | |
| 81003 | <1% | 3,612 | $7K | |
| 87521 | Neg quan hep c or qual rna | <1% | 277 | $7K |
| D0210 | Intraoral - complete series of radiographic images | <1% | 825 | $7K |
| 93225 | <1% | 125 | $7K | |
| 90710 | <1% | 917 | $7K | |
| 72170 | <1% | 887 | $7K | |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 34 | $7K |
| 82670 | <1% | 242 | $7K | |
| 57460 | <1% | 14 | $7K | |
| 81400 | <1% | 183 | $7K | |
| 10120 | <1% | 37 | $6K | |
| 93320 | <1% | 139 | $6K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,044 | $6K |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 241 | $6K |
| 81255 | <1% | 183 | $6K | |
| 85045 | <1% | 2,195 | $6K | |
| 96156 | <1% | 69 | $6K | |
| 82977 | <1% | 928 | $6K | |
| 81251 | <1% | 182 | $6K | |
| 81200 | <1% | 181 | $6K | |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 78 | $6K |
| 92555 | <1% | 156 | $5K | |
| 99407 | <1% | 211 | $5K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,345 | $5K |
| 96402 | <1% | 176 | $5K | |
| 86376 | <1% | 379 | $5K | |
| 97032 | <1% | 354 | $5K | |
| 88141 | <1% | 272 | $5K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 12 | $5K |
| 86140 | <1% | 2,236 | $5K | |
| 81260 | <1% | 185 | $5K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 13,937 | $5K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,637 | $5K |
| 82247 | <1% | 1,211 | $5K | |
| 86696 | <1% | 401 | $5K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,189 | $5K |
| 72131 | <1% | 28 | $5K | |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 270 | $5K |
| 90653 | <1% | 277 | $5K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,712 | $5K |
| 90662 | <1% | 366 | $4K | |
| 97168 | <1% | 75 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,796 | $4K |
| 97035 | <1% | 306 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,523 | $4K |
| 85007 | <1% | 2,861 | $4K | |
| 90696 | <1% | 756 | $4K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 156 | $4K |
| 97116 | <1% | 154 | $4K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $4K |
| 82947 | <1% | 1,063 | $4K | |
| 86593 | <1% | 1,411 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,829 | $4K |
| 85651 | <1% | 1,677 | $4K | |
| 99412 | <1% | 129 | $4K | |
| 59425 | <1% | 76 | $4K | |
| 11981 | <1% | 27 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 96 | $4K |
| 51726 | <1% | 15 | $4K | |
| 73521 | <1% | 173 | $4K | |
| 82310 | <1% | 1,017 | $4K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 307 | $4K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,341 | $4K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 779 | $4K |
| 92551 | <1% | 5,045 | $4K | |
| 87400 | <1% | 148 | $4K | |
| 69200 | <1% | 42 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 808 | $3K |
| 82397 | <1% | 1,843 | $3K | |
| 96368 | <1% | 547 | $3K | |
| 92227 | <1% | 198 | $3K | |
| 0074A | <1% | 74 | $3K | |
| 93308 | <1% | 32 | $3K | |
| 87070 | <1% | 908 | $3K | |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 13 | $3K |
| 93017 | <1% | 55 | $3K | |
| 86695 | <1% | 337 | $3K | |
| 80165 | <1% | 575 | $3K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 4,103 | $3K |
| 82952 | <1% | 380 | $3K | |
| 84703 | <1% | 922 | $3K | |
| 85018 | <1% | 2,561 | $3K | |
| 94760 | <1% | 1,752 | $3K | |
| 87040 | <1% | 1,356 | $3K | |
| 92202 | <1% | 115 | $3K | |
| 85379 | <1% | 2,026 | $3K | |
| 29130 | <1% | 28 | $3K | |
| T2022 | Case management, per month | <1% | 238 | $3K |
| J7510 | Prednisolone oral, per 5 mg | <1% | 2,935 | $3K |
| 20550 | <1% | 25 | $2K | |
| 76942 | <1% | 18 | $2K | |
| 0154A | <1% | 70 | $2K | |
| 82010 | <1% | 2,346 | $2K | |
| 99386 | <1% | 25 | $2K | |
| 96160 | <1% | 199 | $2K | |
| 72190 | <1% | 127 | $2K | |
| 76377 | <1% | 13 | $2K | |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 39 | $2K |
| 70360 | <1% | 85 | $2K | |
| 0012A | <1% | 105 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,721 | $2K |
| 90694 | <1% | 193 | $2K | |
| 84481 | <1% | 161 | $2K | |
| 90714 | <1% | 179 | $2K | |
| 92002 | <1% | 37 | $2K | |
| 99242 | <1% | 26 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,356 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,872 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,935 | $2K |
| 96380 | <1% | 232 | $2K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 448 | $2K |
| 99173 | <1% | 5,509 | $2K | |
| 90678 | <1% | 29 | $2K | |
| 90849 | <1% | 21 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 851 | $2K |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 382 | $2K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 112 | $2K |
| 99152 | <1% | 259 | $1K | |
| 85060 | <1% | 90 | $1K | |
| 92552 | <1% | 37 | $1K | |
| 88342 | <1% | 25 | $1K | |
| 84132 | <1% | 510 | $1K | |
| 93247 | <1% | 12 | $1K | |
| 76813 | <1% | 14 | $1K | |
| 17250 | <1% | 15 | $1K | |
| 0011A | <1% | 112 | $1K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 5,584 | $1K |
| 86708 | <1% | 152 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 732 | $1K |
| 0083A | <1% | 31 | $1K | |
| 99397 | <1% | 68 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 754 | $1K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 30 | $1K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 8,447 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,310 | $1K |
| 86255 | <1% | 64 | $1K | |
| D1351 | Sealant - per tooth | <1% | 271 | $1K |
| 15853 | <1% | 20 | $1K | |
| 80069 | <1% | 177 | $1K | |
| D1330 | <1% | 3,386 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,774 | $1K |
| 86580 | <1% | 360 | $1K | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 11,421 | $1K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 387 | $1K |
| 87420 | <1% | 462 | $1K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 125 | $1K |
| 0502F | <1% | 246 | $1K | |
| 92134 | <1% | 25 | $1K | |
| 94727 | <1% | 30 | $1K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,646 | $997.24 |
| D0272 | Bitewings - two radiographic images | <1% | 506 | $957.87 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,941 | $935.13 |
| 87109 | <1% | 92 | $916.20 | |
| 90685 | <1% | 346 | $897.92 | |
| 76775 | <1% | 55 | $893.45 | |
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | <1% | 15 | $885.87 |
| 76881 | <1% | 12 | $884.41 | |
| 86008 | <1% | 15 | $880.99 | |
| 82652 | <1% | 26 | $872.80 | |
| 20552 | <1% | 28 | $871.15 | |
| 83883 | <1% | 61 | $861.01 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,446 | $820.89 |
| 87075 | <1% | 258 | $814.45 | |
| 96376 | <1% | 893 | $813.44 | |
| 93246 | <1% | 12 | $789.97 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 181 | $773.30 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 3,311 | $760.39 |
| D8660 | <1% | 45 | $739.50 | |
| D9222 | <1% | 36 | $735.94 | |
| 82378 | <1% | 53 | $732.89 | |
| D9230 | Inhalation of nitrous oxide / analgesia, anxiolysis | <1% | 143 | $720.00 |
| 83010 | <1% | 69 | $718.23 | |
| 95251 | <1% | 16 | $684.64 | |
| 84445 | <1% | 13 | $673.67 | |
| 86430 | <1% | 142 | $661.98 | |
| 11721 | <1% | 37 | $644.69 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 411 | $621.20 |
| 84112 | <1% | 43 | $566.22 | |
| D5899 | <1% | 46 | $554.91 | |
| 86880 | <1% | 63 | $553.43 | |
| 84520 | <1% | 319 | $540.42 | |
| S0191 | Misoprostol, oral, 200 mcg | <1% | 396 | $523.81 |
| 86160 | <1% | 48 | $513.96 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,636 | $506.00 |
| 73200 | <1% | 12 | $498.67 | |
| 82465 | <1% | 114 | $496.38 | |
| 73660 | <1% | 41 | $478.58 | |
| 74022 | <1% | 25 | $475.28 | |
| Q0166 | Granisetron hydrochloride, 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen | <1% | 224 | $471.34 |
| 87529 | <1% | 16 | $464.13 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,472 | $454.11 |
| D4341 | <1% | 38 | $446.46 | |
| 92588 | <1% | 13 | $444.04 | |
| 90682 | <1% | 93 | $440.30 | |
| 86235 | <1% | 16 | $436.46 | |
| 86705 | <1% | 78 | $428.67 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 376 | $420.91 |
| 87593 | <1% | 12 | $413.37 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 58 | $402.56 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 442 | $376.88 |
| 82955 | <1% | 30 | $355.79 | |
| 88143 | <1% | 13 | $344.98 | |
| D0603 | <1% | 204 | $340.76 | |
| 82784 | <1% | 29 | $338.86 | |
| 87205 | <1% | 350 | $331.39 | |
| 90611 | <1% | 311 | $331.20 | |
| 98960 | <1% | 15 | $327.58 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 316 | $319.57 |
| 86800 | <1% | 25 | $308.74 | |
| D4355 | <1% | 603 | $280.79 | |
| 86225 | <1% | 37 | $279.54 | |
| 73000 | <1% | 15 | $267.53 | |
| 86334 | <1% | 15 | $262.19 | |
| 86709 | <1% | 32 | $260.87 | |
| 90756 | <1% | 12 | $258.72 | |
| 71047 | <1% | 14 | $258.18 | |
| 82172 | <1% | 14 | $250.43 | |
| 88720 | <1% | 553 | $245.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 401 | $243.68 |
| 84165 | <1% | 38 | $225.79 | |
| 86777 | <1% | 14 | $209.60 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 16 | $200.46 |
| 76514 | <1% | 12 | $199.27 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 27 | $181.05 |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 18 | $176.10 |
| 86141 | <1% | 78 | $166.96 | |
| 88280 | <1% | 13 | $166.15 | |
| 83021 | <1% | 268 | $145.98 | |
| 82150 | <1% | 94 | $143.45 | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 242 | $135.95 |
| 90381 | <1% | 39 | $101.25 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 140 | $97.09 |
| G0008 | Administration of influenza virus vaccine | <1% | 540 | $96.92 |
| 80178 | <1% | 26 | $90.65 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 138 | $90.59 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 12 | $86.79 |
| 84155 | <1% | 39 | $86.73 | |
| D0350 | <1% | 13 | $80.30 | |
| 90688 | <1% | 12 | $76.71 | |
| 36416 | <1% | 110 | $70.70 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 21 | $56.93 |
| 90713 | <1% | 12 | $54.97 | |
| 3078F | <1% | 65,328 | $53.12 | |
| 90380 | <1% | 13 | $50.70 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 109 | $50.45 |
| 82553 | <1% | 38 | $46.71 | |
| 81015 | <1% | 19 | $46.34 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 53 | $33.19 |
| 3074F | <1% | 66,529 | $27.71 | |
| 3079F | <1% | 26,369 | $25.00 | |
| 3075F | <1% | 17,801 | $25.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 51 | $22.71 |
| 86701 | <1% | 59 | $20.00 | |
| 82540 | <1% | 356 | $19.44 | |
| 87077 | <1% | 116 | $17.46 | |
| 85660 | <1% | 12 | $16.49 | |
| 85384 | <1% | 12 | $12.24 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 13 | $10.01 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 12 | $6.29 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 32 | $5.34 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 25 | $4.40 |
| 1159F | <1% | 7,022 | $0.82 | |
| 1160F | <1% | 5,268 | $0.82 | |
| 3077F | <1% | 13,095 | $0.66 | |
| 3080F | <1% | 5,238 | $0.25 | |
| D0601 | 0% | 36 | $0.00 | |
| 3044F | 0% | 320 | $0.00 | |
| 80050 | General health panel | 0% | 284 | $0.00 |
| 4293F | 0% | 953 | $0.00 | |
| 99429 | 0% | 131 | $0.00 | |
| 71020 | 0% | 105 | $0.00 | |
| D1310 | 0% | 190 | $0.00 | |
| 87301 | 0% | 13 | $0.00 | |
| 1220F | 0% | 1,670 | $0.00 | |
| 99406 | 0% | 739 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 14 | $0.00 |
| 44388 | 0% | 14 | $0.00 | |
| 90474 | 0% | 25 | $0.00 | |
| 1126F | 0% | 17 | $0.00 | |
| 1170F | 0% | 38 | $0.00 | |
| 99499 | 0% | 7,874 | $0.00 | |
| 99408 | 0% | 828 | $0.00 | |
| D0190 | 0% | 604 | $0.00 | |
| 99080 | 0% | 5,883 | $0.00 | |
| 86431 | 0% | 12 | $0.00 | |
| 48510 | 0% | 36 | $0.00 | |
| 71010 | 0% | 28 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 14 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| 2022F | 0% | 13 | $0.00 | |
| 3725F | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKARLIN, MARJI (CHIEF REVENUE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.